Common sense drives risk factor screening for systemic psoriasis therapy
November 20, 2015|Dermatology News
Author and Disclosure Information
EXPERT ANALYSIS FROM SDEF LAS VEGAS DERMATOLOGY SEMINAR
Dr. Duffin reported receiving research support from and consulting for Amgen, Eli Lilly, Janssen, Stiefel, AbbVie, Bristol-Myers Squibb, Celgene, Novartis, and XenoPort; consulting and being on the scientific advisory board for Pfizer; and being on the scientific advisory board for Novartis, Eli Lilly, Janssen, Celgene, and XenoPort.
SDEF and this news organization are owned by the same parent company.
On Twitter @karioakes
